Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOX) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 120,400 shares, a growth of 12.4% from the August 31st total of 107,100 shares. Based on an average trading volume of 901,000 shares, the short-interest ratio is presently 0.1 days.

Bionomics Stock Performance

Shares of NASDAQ:BNOX traded up $0.01 during trading on Friday, reaching $0.64. The stock had a trading volume of 119,341 shares, compared to its average volume of 447,413. The business’s 50-day moving average price is $0.64 and its 200 day moving average price is $0.81. Bionomics has a 52 week low of $0.50 and a 52 week high of $6.41.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Bionomics in a research note on Thursday, August 1st.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned about 15.03% of Bionomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.